Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions highlight the promising trial results, such as over 25% of patients experiencing remission or fibrosis reversal, and emphasize the potential of resmetirom as a groundbreaking treatment, with tone and wording indicative of optimism and significance. The tone includes words like 'exciting,' 'approval,' and 'potential,' underscoring a shared perception of impactful medical advancement.
Most discussions express positive reactions, acknowledgment of the study's significance, and approval for resmetirom's potential benefits.
The audience shows high curiosity, with many posts mentioning the drug's implications, FDA approval, and potential to reverse liver fibrosis.
There are in-depth comments referencing specific trial results, mechanisms of action, and comparisons to other treatments, indicating deep involvement.
The excitement around FDA approval, mention of potential revolution in treatment, and stock price movements demonstrate high perceived influence.
This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/Sa0XRPmU5C #Endocrinology https://t.co/r9IY76w5Z9
You know I like to ask provocative questions
1/ ⏰ for #EBGI
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/MbDCaRkDCo https://t.co/ml58cMKi2Z
Resmetiron, aprobado por la FDA para el tto de nuestros pacientes con #MASLD. Nos tocará esperar una temporada para que la EMA lo apruebe y podamos disponer de este fármaco en España, pero ¿porqué no nos vamos preparando? Me explico... / ... https://t.co/gfHvWNzy7I https://t.co/hXxpHruhq2
This video discusses the phase 3 trial of resmetirom, which shows promising results in treating NASH and liver fibrosis. The study reports higher NASH resolution and fibrosis improvement, with significant cholesterol…
This video discusses resmetirom, a new oral treatment for nonalcoholic steatohepatitis, highlighting its potential to resolve NASH and improve liver fibrosis based on recent clinical trial results.
A groundbreaking medical innovation, Resmetirom, shows promise in reducing liver fat and improving liver function in NASH patients, potentially transforming future liver care and offering hope for millions.
This video reviews the promising phase 3 trial data of resmetirom, the first FDA-approved medication for NASH, showing significant improvement in liver fibrosis and disease resolution over 52 weeks, potentially…
Resmetirom shows potential as an effective oral therapy for NASH with liver fibrosis, demonstrating higher rates of disease resolution and fibrosis improvement in a phase 3 trial compared to placebo.
Recent studies show promising results for treating NASH with new drugs Resmetirom and Pegozafermina. These medications, evaluated in clinical trials, demonstrate significant improvement in liver fibrosis and NASH…
This episode discusses liver pathologies associated with metabolic dysfunction, focusing on MASLD, formerly NAFLD. Expert insights highlight current research, diagnostic approaches, and potential treatments for fatty…
Join us this week for a brief tour of some body systems as we review five medications approved by the FDA in 2024. From liver disease to Alzheimer's, we look at Rezdiffra, Iqirvo, Vafseo, Entyvio, and Kisunla, exploring…
RT @ChristianLHorn: ESSENCE vs. MAESTRO-NASH
RT @ChristianLHorn: ESSENCE vs. MAESTRO-NASH
RT @ChristianLHorn: ESSENCE vs. MAESTRO-NASH
ESSENCE vs. MAESTRO-NASH
RT @theliverdr: Brilliant new study on drug treatment of non-alcoholic fatty liver disease https://t.co/8LCyfDXreH A new drug called Resm…
Obinutuzumab Efficacy in Active Lupus Nephritis A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | New England Journal of Medicine https://t.co/D6akvQEZOY
Use of Resmetirom for MAFLD. https://t.co/8mVhDgT9w8
Sources Non-alcoholic fatty liver disease (NAFLD) progression figure: https://t.co/JjSFyjzC3k Resmetirom: https://t.co/80Gyvz9JYp Survodutide: https://t.co/rDaYN3Vraq Tirzepatide: https://t.co/m7Mo9hEruE Prevalence and forecasting of NAFLD: https://t.co/ouAHIQvjcG
RT @theliverdr: Brilliant new study on drug treatment of non-alcoholic fatty liver disease https://t.co/8LCyfDXreH A new drug called Resm…
RT @DrAkhilX: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/MbDCaRkDCo https://t.co/ml58…
RT @DrAkhilX: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/MbDCaRkDCo https://t.co/ml58…
RT @DrAkhilX: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/MbDCaRkDCo https://t.co/ml58…
RT @DrAkhilX: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/MbDCaRkDCo https://t.co/ml58…
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/MbDCaRkDCo https://t.co/ml58cMKi2Z
it was actually able to reverse NAFLD fibrosis by 1 stage in 25% of patients and another 25% had no progression: https://t.co/NWkKtUA3w8 you can very clearly see this reflected in the stock price too, just a couple days ago the price jumped 50% over night on Q3 sales
https://t.co/5Bdbg9jrRl Are you aware about the drug which could potentially reverse fibrosis and prevent CLD progression ? A new horizon for Fatty liver disease NASH. #medtwitter #neetpg #neetss By What stage of fibrosis can this drug reverse NAFLD ?
@ebtapper @rabataller @scottisaacsmd @mromerogomez This is horrifying. It is also horrifying to me that the treatment of NASH or MASH (metabolic dysfunction-associated steatohepatitis) treatment hadn’t changed, until just recently, since I was in medical school
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | New England Journal of Medicine #resmetirom #NASH #Hepatology https://t.co/Ktr5Wrx8o2
https://t.co/g7I4dSEIRI
Estudios mencionados: Estudio fase III del Resmetirom: https://t.co/ZBBBwTX0U0 Estudios fase II de la tirzepatide: https://t.co/YJGO1AOsI8
RT @scottisaacsmd: Phase 3, RCT of #resmetirom in #MASH with liver fibrosis. https://t.co/GLLh4LTrHa https://t.co/kigxmDpCor
RT @scottisaacsmd: Phase 3, RCT of #resmetirom in #MASH with liver fibrosis. https://t.co/GLLh4LTrHa https://t.co/kigxmDpCor
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | New England Journal of Medicine https://t.co/FOHjSJhx7s
RT @whyeszhu: 以往治疗脂肪肝的主要方法是改变生活方式，包括节食和运动，非常难做到。而一些“护肝药”可能可以帮助减少肝脏炎症，但效果并不确切。现在终于有了真正意义上的治疗脂肪肝的药物，Resmetirom，这个药物可以降低肝炎活动、逆转肝纤维化，降低低密度脂蛋白水平…
@NoureddinMD @EASLedu @NEJM @ArunJSanyalVCU @AlkhouriNaim @RamyYounes9 Rezdiffra: https://t.co/ejLVfbeqFy NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both)
期待大
RT @BertrandBio: 3/ Madrigal: disc. from AEs taken into account in "completers of W52 Liver biopsy" A Phase 3, Randomized, Controlled Tria…
3/ Madrigal: disc. from AEs taken into account in "completers of W52 Liver biopsy" A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/qHuVUaM4p7 https://t.co/XnIZ3LYnri
RT @whyeszhu: 以往治疗脂肪肝的主要方法是改变生活方式，包括节食和运动，非常难做到。而一些“护肝药”可能可以帮助减少肝脏炎症，但效果并不确切。现在终于有了真正意义上的治疗脂肪肝的药物，Resmetirom，这个药物可以降低肝炎活动、逆转肝纤维化，降低低密度脂蛋白水平…
RT @whyeszhu: 以往治疗脂肪肝的主要方法是改变生活方式，包括节食和运动，非常难做到。而一些“护肝药”可能可以帮助减少肝脏炎症，但效果并不确切。现在终于有了真正意义上的治疗脂肪肝的药物，Resmetirom，这个药物可以降低肝炎活动、逆转肝纤维化，降低低密度脂蛋白水平…
Resmeritrom 80 y 100 mg VO OD es superior a placebo con respecto a la resolución de la esteatohepatitis no alcohólica y al menos un estadío de mejoría de la fibrosis hepática #resmeritrom #NASH https://t.co/mPZYAARIP9
Experts discuss first-of-its-kind medication for liver disease on @CommonSpirit's 5-Min Check In: https://t.co/YttbOIig9E @tommcginn4 @sagar_ankita @DignityHealthAZ
Acceso en @PubMedOnline https://t.co/4BUziAveWF
Full text links @NEJM https://t.co/Yg1rnZTXHs Y resumen de la investigación https://t.co/w5YAJYhClu https://t.co/9asuAyXMtd
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | New England Journal of Medicine https://t.co/FKKABIKVtb
@ricsmd Resmetirom - not yet available here :) https://t.co/LwovQQos4V
Access full article here: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | New England Journal of Medicine https://t.co/XckqqFYWIR
RT @ACG_EBGI: 1/ ⏰ for #EBGI
RT @ACG_EBGI: 1/ ⏰ for #EBGI
RT @ACG_EBGI: 1/ ⏰ for #EBGI
RT @ACG_EBGI: 1/ ⏰ for #EBGI
RT @ACG_EBGI: 1/ ⏰ for #EBGI
RT @ACG_EBGI: 1/ ⏰ for #EBGI
RT @ACG_EBGI: 1/ ⏰ for #EBGI
RT @ACG_EBGI: 1/ ⏰ for #EBGI
RT @ACG_EBGI: 1/ ⏰ for #EBGI
RT @ACG_EBGI: 1/ ⏰ for #EBGI
1/ ⏰ for #EBGI
Resmetirom, el primer fármaco aprobado para los hígados grasos. Buenas noticias que llegaran a Canarias pronto... o un poco más tarde... https://t.co/7c7dOBUNRA
非アルコール性脂肪性肝炎（NASH）に対する新薬Resmetiromが米国FDAにおいて迅速承認された。Resmetiromは経口の肝臓指向性甲状腺ホルモン受容体β選択的アゴニスト。 日本で使用できる日も遠くなさそうですね。 https://t.co/ERrOXWjNl8
Resmetirom is the first medication approved to treat nonalcoholic steatohepatitis! https://t.co/GPmJb5Yyhd
RT @MayoClinicGIHep:
RT @MayoClinicGIHep:
RT @MayoClinicGIHep:
RT @MayoClinicGIHep:
Exciting news for #MASH and #livertwitter with @US_FDA approving resmetirom @NEJM:
RT @whyeszhu: 以往治疗脂肪肝的主要方法是改变生活方式，包括节食和运动，非常难做到。而一些“护肝药”可能可以帮助减少肝脏炎症，但效果并不确切。现在终于有了真正意义上的治疗脂肪肝的药物，Resmetirom，这个药物可以降低肝炎活动、逆转肝纤维化，降低低密度脂蛋白水平…
RT @whyeszhu: 以往治疗脂肪肝的主要方法是改变生活方式，包括节食和运动，非常难做到。而一些“护肝药”可能可以帮助减少肝脏炎症，但效果并不确切。现在终于有了真正意义上的治疗脂肪肝的药物，Resmetirom，这个药物可以降低肝炎活动、逆转肝纤维化，降低低密度脂蛋白水平…
RT @sociedadSEEN:
Link to the research paper showing the Phase 3 trial results from Madrigal Pharmaceuticals. https://t.co/NTbatJYkEG
RT @YAYshamsaldeen:
RT @AnnaGaddy: I'm so far out of IM that I wasn't aware this was coming down the pipeline but this is very cool and just got FDA approval f…
RT @ErickMD24: RESMETIROM •1st drug to be FDA approved for NASH •Liver directed thyroid hormone receptor agonist (THR-beta) •80-mg dose &…
RESMETIROM •1st drug to be FDA approved for NASH •Liver directed thyroid hormone receptor agonist (THR-beta) •80-mg dose & 100-mg resmetirom superior to placebo with respect to NASH resolution #PCEDM2024 https://t.co/cGfZJn5MvW
RT @AnnaGaddy: I'm so far out of IM that I wasn't aware this was coming down the pipeline but this is very cool and just got FDA approval f…
I'm so far out of IM that I wasn't aware this was coming down the pipeline but this is very cool and just got FDA approval for NASH treatment. Pretty compelling numbers to me as a me layperson. https://t.co/KEJHi4sWs9
RT @JCrippsSciGuy: Drug approval for NASH
Drug approval for NASH
https://t.co/789e9Y2xOY https://t.co/KQMzsXjBjf
RT @DrJavierCrespo: Resmetiron, aprobado por la FDA para el tto de nuestros pacientes con #MASLD. Nos tocará esperar una temporada para que…
RT @DrJavierCrespo: Resmetiron, aprobado por la FDA para el tto de nuestros pacientes con #MASLD. Nos tocará esperar una temporada para que…
RT @DrJavierCrespo: Resmetiron, aprobado por la FDA para el tto de nuestros pacientes con #MASLD. Nos tocará esperar una temporada para que…
RT @DrJavierCrespo: Resmetiron, aprobado por la FDA para el tto de nuestros pacientes con #MASLD. Nos tocará esperar una temporada para que…
RT @DrJavierCrespo: Resmetiron, aprobado por la FDA para el tto de nuestros pacientes con #MASLD. Nos tocará esperar una temporada para que…
RT @DrJavierCrespo: Resmetiron, aprobado por la FDA para el tto de nuestros pacientes con #MASLD. Nos tocará esperar una temporada para que…
Get to know Resmetirom!
Resmetiron, aprobado por la FDA para el tto de nuestros pacientes con #MASLD. Nos tocará esperar una temporada para que la EMA lo apruebe y podamos disponer de este fármaco en España, pero ¿porqué no nos vamos preparando? Me explico... / ... https://t.co/gfHvWNzy7I https://t.co/hXxpHruhq2
RT @YAYshamsaldeen:
RT @YAYshamsaldeen:
RT @YAYshamsaldeen:
RT @YAYshamsaldeen:
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @YAYshamsaldeen:
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @melina_manolas: !!!!! FDA approves first medication for the treatment of NASH (or MASH) with Resmetirom - an oral, liver-directed thyro…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
RT @melina_manolas: !!!!! FDA approves first medication for the treatment of NASH (or MASH) with Resmetirom - an oral, liver-directed thyro…
RT @melina_manolas: !!!!! FDA approves first medication for the treatment of NASH (or MASH) with Resmetirom - an oral, liver-directed thyro…
RT @MWeintraubMD: Today, the FDA approved resmetirom, a thyroid hormone receptor partial activator, for the treatment of NASH. Resmetirom…
#Rezdiffra, a small molecule, targets a certain liver receptor to spark fat-reducing effects. In a Phs 3 trial enrolling patients w/ biopsy-confirmed #NASH, results also showed improvement in #fibrosis, or liver scarring. @NEJM published Ph 3 data in Feb. https://t.co/DaRLzI5LRj
RT @melina_manolas: !!!!! FDA approves first medication for the treatment of NASH (or MASH) with Resmetirom - an oral, liver-directed thyro…
RT @melina_manolas: !!!!! FDA approves first medication for the treatment of NASH (or MASH) with Resmetirom - an oral, liver-directed thyro…
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM https://t.co/SVvYaXbA5M
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage https://t.co/kQKhUT2PTP
RT @IlindelatorreMD: Los resultados se publicaron en línea el 7 de febrero en el New England Journal of Medicine . https://t.co/T7OYHl78E…
RT @IlindelatorreMD: Los resultados se publicaron en línea el 7 de febrero en el New England Journal of Medicine . https://t.co/T7OYHl78E…
RT @IlindelatorreMD: Los resultados se publicaron en línea el 7 de febrero en el New England Journal of Medicine . https://t.co/T7OYHl78E…
Los resultados se publicaron en línea el 7 de febrero en el New England Journal of Medicine . https://t.co/T7OYHl78Eq https://t.co/aZZ0A8vWUj
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM https://t.co/Mpkyi0mq9T
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM https://t.co/DEMARmZuh7
RT @NEJM: Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH phase 3 trial)…
https://t.co/4IQ1QX4eu3 https://t.co/KJAfuWh8It
Journal Club SID Il ruolo del resmetiron nella NASH con fibrosi: il trial di fase 3 MAESTRO-NASH - A cura di Alessandro Mantovani https://t.co/BFFIqZGKkY
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
RT @nicknorwitz: You know I like to ask provocative questions
You know I like to ask provocative questions
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/XJRQtTlTzV
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @JulesLevin1: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM about to be FDA approved soon htt…
RT @JulesLevin1: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM https://t.co/FlHrrjugmp
RT @gastromx: Fuente: https://t.co/SgyDufLyyB #innovacióncienciayconvivencia #amg2024 #yosoyAMG #Innovación #Ciencia #Convivencia https://…
Fuente: https://t.co/SgyDufLyyB #innovacióncienciayconvivencia #amg2024 #yosoyAMG #Innovación #Ciencia #Convivencia https://t.co/oXVJl3IJPC
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis - PubMed @MadrigalPharma
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM https://t.co/jhF1LRoKak
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
RT @NEJM: This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Live…
This week’s most viewed articles: 1. Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/Sa0XRPmU5C #Endocrinology https://t.co/r9IY76w5Z9
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM https://t.co/FlHrrjugmp
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM about to be FDA approved soon https://t.co/FlHrrjugmp
✅経口甲状腺ホルモン受容体β選択的刺激薬（レスメチロム）によるNASH改善効果 話題の論文読みました
Trending on PubMed: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. https://t.co/OPnbsJO6RL
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/Pw8peIpvni
RT @NEJM: Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH phase 3 trial)…
RT @NEJM: Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH phase 3 trial)…
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/yO24O0FaIH #Liver
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis https://t.co/vWhZRARH6Y #hvhebron #hepato @NEJM
RT @NEJM: Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH phase 3 trial)…
RT @NEJM: Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH phase 3 trial)…
RT @NEJM: Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH phase 3 trial)…
RT @NEJM: Original Article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH phase 3 trial)…
NASHの薬、効いとるやんけ！ https://t.co/RxsEfx0loq
https://www.nejm.org/doi/full/10.1056/NEJMoa2309000
RT @ReibergerThomas: #LiverTwitter @MedUni_Wien RESMETIROM liver-directed thyroid hormone receptor beta agonist : 966 pts fatty liver dis…
RT @ReibergerThomas: #LiverTwitter @MedUni_Wien RESMETIROM liver-directed thyroid hormone receptor beta agonist : 966 pts fatty liver dis…
RT @ReibergerThomas: #LiverTwitter @MedUni_Wien RESMETIROM liver-directed thyroid hormone receptor beta agonist : 966 pts fatty liver dis…
RT @ReibergerThomas: #LiverTwitter @MedUni_Wien RESMETIROM liver-directed thyroid hormone receptor beta agonist : 966 pts fatty liver dis…
RT @ReibergerThomas: #LiverTwitter @MedUni_Wien RESMETIROM liver-directed thyroid hormone receptor beta agonist : 966 pts fatty liver dis…
Phase 3, RCT of #resmetirom in #MASH with liver fibrosis. https://t.co/UrbhLyER8h https://t.co/8BT49jsgb7
RT @ReibergerThomas: #LiverTwitter @MedUni_Wien RESMETIROM liver-directed thyroid hormone receptor beta agonist : 966 pts fatty liver dis…
RT @ReibergerThomas: #LiverTwitter @MedUni_Wien RESMETIROM liver-directed thyroid hormone receptor beta agonist : 966 pts fatty liver dis…
#LiverTwitter @MedUni_Wien RESMETIROM liver-directed thyroid hormone receptor beta agonist : 966 pts fatty liver disease #MASH
FZ
AM